You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

108 Results
Document
Blog post
Our websites have been completely redesigned to be mobile-friendly, accessible to everyone and to make it as easy as possible for you to quickly find...
Nov 2017
Symptom Management
Drug
Other Name(s): Tasigna®
Jul 2025
Drug
Other Name(s): Abraxane®
Dec 2024
Drug
Other Name(s): Atriance®
Apr 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Jul 2025

Pages